Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.42M 2.24M 2.1M 3.93M 262M 3.96M 26.57M 10.3M 129M 10.41M 10.19M 447M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.65M 8.02M 7.5M 14.07M 937M 14.16M 95.09M 36.85M 461M 37.26M 36.46M 1.6B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 77 30/11/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-1.25%+63.52%+114.88% 54.44B
+4.60%+3.02%+58.20%+47.16% 45.8B
-1.44%+0.39%-12.94%-19.24% 22.98B
-2.69%-2.10%-3.68%+379.00% 20.76B
+3.22%-0.84%+27.88%-34.00% 16.25B
+0.58%+1.08%+16.73%-38.06% 15.34B
-1.01%-2.30%+27.42%+171.92% 13.05B
+3.07%+0.14%+29.37% - 12.37B
+4.95%+11.70%+123.63%+252.19% 12.47B
Average +1.41%+2.23%+36.68%+109.23% 23.72B
Weighted average by Cap. +1.63%+1.49%+40.86%+99.91%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.06 0.1 6.9 0.1 0.7 0.27 3.4 0.27 0.27 11.79 0.14 0.12 0.11 0.1 0.19 12.77 0.19 1.3 0.5 6.29 0.51 0.5 21.83
Net income -3.1M -2.71M -2.51M -2.35M -4.4M -293M -4.43M -29.74M -11.53M -144M -11.65M -11.4M -501M -18.47M -16.11M -14.92M -13.97M -26.19M -1.74B -26.35M -177M -68.59M -858M -69.35M -67.86M -2.98B
Net Debt 7.1M 6.19M 5.73M 5.36M 10.06M 669M 10.12M 67.97M 26.34M 330M 26.63M 26.06M 1.14B 7.15M 6.24M 5.78M 5.41M 10.14M 675M 10.2M 68.53M 26.56M 332M 26.85M 26.27M 1.15B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!